Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

未开盘 09-25 16:00:00 EDT

15.61

-0.77

-4.70%

盘后15.65

+0.04+0.26%

19:59 EDT

最高16.58	最低15.55	成交量380.80万
今开16.45	昨收16.38	日振幅6.29%
总市值124.53亿	流通市值23.78亿	总股本7.98亿
成交额6,069万	换手率2.50%	流通股本1.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":15.61,"timestamp":1790366400000,"preClose":16.38,"halted":0,"volume":3807975,"hourTrading":{"tag":"盘后","latestPrice":15.65,"preClose":15.61,"latestTime":"19:59 EDT","volume":120052,"amount":1875685.0371,"timestamp":1790380754318,"change":0.04,"changeRate":0.002562,"amplitude":0.017937},"delay":0,"changeRate":-0.04700854700854699,"floatShares":152343050,"shares":797749602,"eps":-1.117703,"marketStatus":"未开盘","change":-0.77,"latestTime":"09-25 16:00:00 EDT","open":16.45,"high":16.5807,"low":15.55,"amount":60688999.902449995,"amplitude":0.062924,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.117703,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":0,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":16.38,"preHourTrading":{"tag":"盘前","latestPrice":16.45,"preClose":16.38,"latestTime":"09:29 EDT","volume":4300,"amount":70890.359,"timestamp":1790342999999,"change":0.07,"changeRate":0.004274,"amplitude":0.019963},"postHourTrading":{"tag":"盘后","latestPrice":15.65,"preClose":15.61,"latestTime":"19:59 EDT","volume":120052,"amount":1875685.0371,"timestamp":1790380754318,"change":0.04,"changeRate":0.002562,"amplitude":0.017937},"volumeRatio":0.5877413089126206,"optionData":{"bulkOrders":[{"symbol":"SMMT","call":true,"expireDate":1792123200000,"strike":"20.0","timestamp":1790366274520,"price":1.2,"volume":1500,"amount":180000,"type":"-"}]},"impliedVol":1.7284,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1165568594","title":"异动解读｜Summit Therapeutics盘中下跌5.03%，FDA审批不确定性持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165568594","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165568594?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:55","pubTimestamp":1790182552,"startTime":"0","endTime":"0","summary":"9月23日，Summit Therapeutics盘中下跌5.03%，报16.2593美元/股，成交额3472.72万美元。消息面上，尽管公司核心药物依沃西单抗近期在WCLC及ESMO等国际学术会议上密集披露积极临床数据，但市场焦点已转向FDA审批的不确定性。此前披露的HARMONi全球III期研究主要OS分析未达统计学显著性，而FDA曾明确指出该适应症需要统计学显著的OS获益，仅凭PFS数据可能不足以支持上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Summit股价下跌，FDA审批悬念压制市场","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199769998","title":"依沃西单抗联合化疗对比度伐利尤单抗联合化疗一线治疗晚期胆道癌中国患者——Harmoni-Gi1 III期临床研究入选ESMO 2026主席研讨会","url":"https://stock-news.laohu8.com/highlight/detail?id=1199769998","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199769998?lang=zh_cn&edition=full","pubTime":"2026-09-22 18:01","pubTimestamp":1790071305,"startTime":"0","endTime":"0","summary":"来自中国的Harmoni-Gi1研究即将在2026年欧洲肿瘤内科学会（ESMO）主席研讨会上惊艳亮相。这项III期临床试验聚焦于晚期胆道癌患者的一线治疗，核心比较对象为依沃西单抗（Ivonescimab）联合化疗方案与度伐利尤单抗（Durvalumab）联合化疗方案。这一重磅研究的入选，无疑为其在肿瘤学界的地位增添了浓墨重彩的一笔。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188336591","title":"异动解读｜Summit Therapeutics盘中下跌5.13%，报16.935美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188336591","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188336591?lang=zh_cn&edition=full","pubTime":"2026-09-21 23:19","pubTimestamp":1790003960,"startTime":"0","endTime":"0","summary":"9月21日，Summit Therapeutics盘中下跌5.13%，报16.935美元/股，成交额2940.2万美元。Summit Therapeutics所在的生物科技行业中，个股表现分化，其中Moderna涨8.82%，Greenland Mines涨236.63%，Hyperliquid Strategies跌0.28%，吉利德科学涨0.61%，安进涨1.58%。Summit Therapeutics是一家生物制药公司，专注于发现、开发和商业化药物疗法，核心候选产品管线聚焦肿瘤治疗领域，旨在成为新时代的标准护理药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103591686","title":"WCLC 2026更新Harmoni数据：依沃西单抗联合化疗在西方与亚洲患者中展现一致总生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1103591686","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103591686?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:01","pubTimestamp":1789466500,"startTime":"0","endTime":"0","summary":"在2026年世界肺癌大会（WCLC）上公布的Harmoni研究更新数据显示，依沃西单抗（Ivonescimab）联合化疗方案，在西方及亚洲患者群体中均呈现出一致的总生存期改善结果。这一发现进一步夯实了该联合疗法跨地域、跨种族的广泛适用性基础，为全球肺癌治疗策略的优化提供了有力循证支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159005380","title":"Shimamura有限公司 - 关于收购业务的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1159005380","media":"投资观察","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159005380?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:42","pubTimestamp":1788745378,"startTime":"0","endTime":"0","summary":"9月7日（路透社）——Shimamura有限公司<8227.T>：*SHIMAMURA有限公司：关于收购业务的通知*SHIMAMURA有限公司：将从Summit Corporation收购其服装业务“COLMOPIA”旗下21家门店的资产及相关权利，并负责运营这些目标门店*SHIMAMURA有限公司：此次业务收购对截至2027年2月的财年合并财务业绩的影响预计将微乎其微*SHIMAMURA有限公司","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4597","BK4504","BK4585","LU0310800965.SGD","BK4532","LU2237443622.USD","SMMT","LU1244550494.USD","LU1267930490.SGD","LU1244550577.SGD","LU0310799852.SGD","LU1267930227.SGD","LU0128525689.USD","BK4588","LU0211327993.USD","LU2237443382.USD","LU1244550221.USD","LU2237443978.SGD","BK4114","LU0052756011.USD","BK4155","LU0211328371.USD","LU2488822045.USD","LU2237443549.SGD","BK4596","TGT","LU0823411888.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664021386","title":"英国8月份新车注册量同比增长约13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664021386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664021386?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:35","pubTimestamp":1788496557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113424300","title":"美股开盘 | 三大指数集体低开，Meta逆势涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113424300","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113424300?lang=zh_cn&edition=full","pubTime":"2026-08-26 21:30","pubTimestamp":1787751030,"startTime":"0","endTime":"0","summary":"8月26日，美股三大指数集体低开，道琼斯指数跌0.01%，标普500指数跌0.13%，纳斯达克综合指数跌0.22%。Meta涨超3%，与美国多个州同意就青少年社交媒体危害案达成和解；Summit Therapeutics涨超10%，核心候选药物依沃西单抗III期试验数据积极；爱芬奇涨超20%，Q2业绩超市场预期，同步上调全年业绩指引；先科电子涨超5%，Q2业绩远超市场预期，Q3业绩指引强劲。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2322448957.HKD","LU0097036916.USD","IE0002270589.USD","NOCT","YMmain","LU0417517546.SGD","IE00BWXC8680.SGD","RSPC","LU0786609619.USD","NAPR","LU0757428866.USD","IE00BMPRXQ63.HKD","LU2505996509.AUD","07261","LU2250418816.HKD","LU2458330169.SGD","LU1642822529.SGD","LU0345769631.USD","LU1861558580.USD","LU0211327993.USD","LU0320765489.SGD","LU0683600562.USD","LU0080751232.USD","QID","LU1803068979.SGD","LU2361044949.HKD","SG9999002232.USD","LU2247934214.USD","SG9999015986.USD","LU0320765059.SGD","SG9999002224.SGD","META","LU0056508442.USD","SG9999018865.SGD","LU0823421416.USD","VOO","LU2242650005.HKD","IE00BJLML261.HKD",".IXIC","LU0265550359.USD","IE0001KFT4U8.USD","LU0234572021.USD","SGXZ31699556.SGD","SMETAmain","LU2023250504.SGD","LU0648001328.SGD","LU1551013425.SGD","LU0109392836.USD","QLD","LU0823434583.USD","LU0082616367.USD","LU2756315664.SGD","SPXS","LU0878866978.SGD","LU1791710400.SGD","IE0004445239.USD","LU1979441026.SGD","LU1564329461.SGD","LU2168564222.USD","LU0949170772.SGD","IE00BJTD4N35.SGD","LU0256863902.USD","SDS","LU1066051498.USD","IE00BJJMRY28.SGD","LU1778281490.HKD","LU2361044865.SGD","DIA","BK4585","LU0979878070.USD","IE00BFSS8Q28.SGD","LU0784385840.USD","LU2487616109.SGD","LU1815333072.USD","TQQY","LU1489326972.SGD","LU0354030438.USD","LU1551013342.USD","IE0034235188.USD","SG9999017495.SGD","LU0787776722.HKD","LU1992135472.HKD","LU1670710588.SGD","LU2552382132.HKD","LU0353189763.USD","LU2404859667.USD","LU0308772762.SGD","DDM","LU0053666078.USD","IE00B19Z3B42.SGD","LU1035775433.USD","LU1670711040.USD","LU0256863811.USD","LU0310799852.SGD","BK4543","LU2168564149.EUR","SGXZ23171101.USD","IE00BQXX3F31.USD","LU0784384876.USD","QQQM","LU0354030511.USD","LU2456880835.USD","FBYY","07568","LU1914381329.SGD","LU1564329628.SGD","IE00BJJMRX11.SGD","LU0234570918.USD","BK4587","LU1823568750.SGD","QTWO","LU0061474960.USD","LU0444973449.USD","SG9999014898.SGD","LU0823421333.USD","SG9999014880.SGD","SQQQ","IE00B4YYXB79.USD","BK4141","LU0719512351.SGD","LU2746668974.SGD","BK4592","IVV","SG9999015952.SGD","03455","SGXZ51526630.SGD","SPDN","07522","HK0000914660.USD","IE00BKDWB100.SGD","LU0198837287.USD","LU2054465674.USD","LU0210533765.USD","LU1861559042.SGD","LU1992135399.USD","LU2764262908.HKD","LU0109391861.USD","IE00B3SWFQ91.USD","IE0034235303.USD","LU0795875169.SGD","IE00B19Z9505.USD","DMAX","LU0912757837.SGD","HK0000304797.USD","IE0009356076.USD","LU1366192091.USD","GB00B4QBRK32.GBP","LU0267386448.USD","FBL","LU0068578508.USD","TRUC","QQQX","IE00B7KXQ091.USD","LU0738911758.USD","LU0957791311.USD","LU2168564495.EUR","LU2272731600.USD","LU2023250330.USD","LU1852331112.SGD","LU2463028550.USD","LU2106854487.HKD","LU2552382215.SGD","LU1564329032.USD","LU2417539215.USD","SSO","IE00BK4W5M84.HKD","BK4524","LU0203201768.USD","LU0642271901.SGD","LU1046421795.USD","HK0000914686.HKD","LU0661504455.SGD","LU2543165471.USD","SMTG","METV","LU0205193047.USD","IE00B1XK9C88.USD","IE00BQXX3C00.GBP","XDAT","LU0203202063.USD","LU2404859741.USD","LU1868837136.USD","LU1935042215.USD","PSQ","LU0566484027.USD","LU1815336091.USD","LU1366333091.USD","LU2272731782.SGD","TQQQ","LU1868837300.USD","SDOW","SPYH","HK0000304805.HKD","IE000ITXATA3.USD","LU2860962120.EUR","NDX","UDOW","IE00BMPRXR70.SGD","LU1429558221.USD",".SPX","LU2322448791.USD","LU1814569148.SGD","LU0070302665.USD","LU1868836591.USD","LU0466842654.USD","LU0726765562.USD","IE00B4JS1V06.HKD","LU0096364046.USD","LU1839511570.USD","LU2272731865.HKD","SMAX","LU0690374961.EUR","LU0348723411.USD","LU1242518857.USD","LU0943347566.SGD","LU0265550946.USD","LU2403377893.USD","LU2360032135.SGD","IE00B775H168.HKD","SOCL","IE00BN29S564.USD","LU2361045086.USD","LU0130102774.USD","LU0820561909.HKD","LU2087625088.SGD","IE00B7SZLL34.SGD","BK4077","LU0552385451.USD","LU1564329115.USD","LU1059921491.USD","LU0985320562.USD","LU1201861249.SGD","GXPC","LU1235294995.USD","BK4539","NJUL","DOG","GAMR","LU0157215616.USD","SPXU","LU1571399168.USD","LU1670628061.USD","NJAN","LU0162691827.USD","LU1670711123.USD","LU1868836914.USD","BK4023","LU1629891620.HKD","FBX","LU0127658192.USD","LU1232071149.USD","LU0061475181.USD","SGXZ99366536.SGD","LU0011850046.USD","LU2720916845.USD","IE00BQXX3D17.EUR","LU0889565833.HKD","IE000SO60NU8.SGD","LU0689472784.USD","LU0795875086.SGD","LU0012050646.USD","LU0210528500.USD","IE0005OL40V9.USD","LU1069344957.HKD","LU1670627923.USD","LU1242518931.SGD","LU0553294199.USD","MMAX","LU1815336760.USD","GB00B4LPDJ14.GBP","LU0672654240.SGD","YSPY","LU0276348264.USD","LU1496350502.SGD","LU0949170426.SGD","LU0215105999.USD","LU0724617625.USD","LU0476273544.USD","LU2097829019.USD","LU0640476718.USD","LU2764263039.SGD","LU2023250843.SGD","LU0072461881.USD","LU1116320737.USD","LU2237957811.SGD","SMTC","LU0210536198.USD","LU1127390331.HKD","LU2065171402.SGD","LU0208291251.USD","LU1868836757.USD","QDEC","LU0690374615.EUR","LU1935043023.USD","GB00BDT5M118.USD","SH","VOX","LU0820561818.USD","LU1153585028.USD","UPRO","LU1301847155.USD","LU0133085943.USD","LU1732799900.SGD","LU2505996681.GBP","SPUU","LU1316542783.SGD","LU1145028129.USD","LU2488822045.USD","OGIG","IE00B5949003.HKD","SPY","FBY","LU1974910355.USD","LU1791710582.SGD","LU1674673691.USD","LU0203345920.USD","03034","02834","IE000W1ABFV2.USD","LU0096362180.USD","XLC","LU0170899867.USD","LU2430703095.HKD","LU2420271590.USD","LU1935042488.USD","IE000YTNTUN2.SGD","METU","SG9999004303.SGD","LU2326559502.SGD","LU1917777945.USD","LU1548497426.USD","NULC","LU2430703251.USD","LU0323591593.USD","IE00BJTD4V19.USD","LU1559883803.SGD","LU1003077747.HKD","LU0820562030.AUD","LU0980610538.SGD","LU2168563687.JPY","LU2125154935.USD","LU0203347892.USD","LU0784383803.USD","SG9999018857.SGD","LU1267930490.SGD","LU2381873111.SGD","IE00B19Z8X17.USD","09834","FCOM","LU2756315318.SGD","LU0154236417.USD","SGXZ80539844.SGD","LU2602419157.SGD","LU0314104364.USD","LU1720051108.HKD","LU1720051017.SGD","LU0070217475.USD","LU2357305700.SGD","LTL","LU0316494557.USD","LU1119994496.HKD","LU0077335932.USD","LU0823434740.USD","LU0957808578.USD","LU2462591350.SGD","LU2063271972.USD","IE000BZT7R73.USD","LU1435385759.SGD","07266","SG9999001077.SGD","BK4507","LU2458330243.SGD","IE00BFSS7M15.SGD","SG9999015945.SGD","LU2473716301.USD","SGXZ81514606.USD","LU2087621335.USD","LU2746668461.USD","LU2244417387.USD","IE00B19Z8W00.USD","LU0174119429.USD","LU0985489474.SGD","LU1116320901.HKD","LU1074936037.SGD","LU2764263203.CNY","METD","IE0009G5SDU7.USD","METW","LU0225283273.USD","SPYU","SPYM","BK4007","IE0003U64NQ7.SGD","LU0072462426.USD","LU0882574139.USD","LU2168564065.EUR","LU0211331839.USD","03086","LU1267930730.SGD","LU0211328371.USD","IE000MB6IJN5.SGD","09086","IE00BK4W5L77.USD","BK4588","LU1699723380.USD","LU2265009873.SGD","QMAR","SG9999015978.USD","LU2133065610.SGD","LU1988902786.USD","LU2592432038.USD","LU0149725797.USD","BK4139","LU2461242641.AUD","LU0708995401.HKD","LU2430703178.SGD","LU2213496289.HKD","LU0061474705.USD","LU1670710661.SGD","LU2236285917.USD","HIBL","LU0079474960.USD","SPXL","METG","LU1697837992.HKD","LU2065170008.USD","IE0000B7K699.USD",".DJI","LU0444971666.USD","BK4094","LU0006306889.USD","LU2264538146.SGD","LU2347655156.SGD","LU0205194284.USD","IE000F7OJYX1.SGD","LU0106261612.USD","LENZ","LU2347655073.USD","LU0106261372.USD","IE00B1BXHZ80.USD","DXD","LU0433182093.SGD","LU2125154778.USD","LU2317271919.USD","LU0187121727.USD","LU1066053197.SGD","LU1935043536.SGD","LU1261432733.SGD","GPIQ","SG9999014914.USD","LU2360106780.USD","LU0353189680.USD","LU1718418525.SGD","IE00BMPRXN33.USD","ANF","LU1732800096.USD","LU2065171311.SGD","LU2462157665.USD","METQ","LU0964807845.USD","SPYQ","LU1804176565.USD","LU0528227936.USD","LU2237957902.USD","LU2896262040.SGD","LU1064131342.USD","SMMT","IE000WAW04H5.SGD","LU0784385170.HKD","LU0788109477.HKD","LU0345769128.USD","LU1674673428.USD","LU2065169927.USD","LU0545039389.USD","IE00B19Z3581.USD","IE0004445015.USD","LU1280957306.USD","IE000KEQY171.SGD","QQQ","LU1084165304.USD","SG9999014906.USD","LU1935042991.SGD","LU2552382058.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662971198","title":"疗效碾压阿斯利康Imfinzi！Summit依沃西单抗III期试验数据积极，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2662971198","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662971198?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:41","pubTimestamp":1787748060,"startTime":"0","endTime":"0","summary":"8月26日，$Summit Therapeutics$股价一度大涨逾16%，此前该公司公布了后期试验的积极数据。结果显示，其核心候选药物依沃西单抗在疗效上超越了$阿斯利康$旗下的癌症药物Imfinzi。该项名为HARMONi-GI1的III期试验由Summit的中国合作方主导，旨在评估依沃西单抗联合化疗方案，对比度伐利尤单抗联合化疗方案，用于一线治疗晚期胆道癌的疗效。Summit进一步指出，这款双特异性抗体还在关键次要终点——无进展生存期和客观缓解率上达到了预期目标。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486352.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662671167","title":"疗效碾压阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西单抗III期试验数据积极，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662671167?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:32","pubTimestamp":1787747523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","LU1829250122.USD","LU2456880835.USD","III","LU2237443622.USD","LU2417539215.USD","LU2488822045.USD","LU0708994859.HKD","LU0109394709.USD","AZN","LU2089984988.USD","LU2237443382.USD","LU2236285917.USD","LU2462157665.USD","LU1267930573.SGD","LU2468319806.SGD","LU2237443549.SGD","BK4007","BK4588","LU0058720904.USD","LU0310800379.SGD","AZNH","LU0289739699.SGD","LU0432979614.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0320765992.SGD","SMMT","LU0128525929.USD","LU0029864427.USD","BK4585","BK4568","BK4139","LU2237443465.HKD","LU2237443895.HKD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180030710","title":"康方生物中国单区域试验：依沃西单抗联合化疗一线治疗晚期胆道癌，总生存期获益显著优于度伐利尤单抗联合化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1180030710","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180030710?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:01","pubTimestamp":1787695272,"startTime":"0","endTime":"0","summary":"在一项由康方生物在中国进行的单区域试验中，依沃西单抗联合化疗作为晚期胆道癌的一线治疗方案，展现出相较于度伐利尤单抗联合化疗具有统计学显著性的总生存期优势。该项研究聚焦于既往未经治疗的晚期胆道癌患者群体。试验数据显示，依沃西单抗组合疗法在延长患者总生存期方面表现更为突出，其差异达到了统计学显著水平。这一结果无疑为胆道癌这一预后相对较差的恶性肿瘤领域，注入了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116076631","title":"Leerink Partners上调Summit Therapeutics评级：从“跑输大市”调升至“与大盘持平”，目标价从12美元升至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116076631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116076631?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:39","pubTimestamp":1786531157,"startTime":"0","endTime":"0","summary":"Leerink Partners对Summit Therapeutics Inc.的评级进行了调整。这家投资机构将该公司股票从“跑输大市”的评级上调至“与大盘持平”。同时，目标价也由此前的12美元提升至13美元。这一变动反映出市场对该公司的前景评估有所改观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182231349","title":"Summit Therapeutics启动膀胱癌药物Ivonescimab全球II/III期Harmoni-Gu1试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1182231349","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182231349?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:09","pubTimestamp":1785928189,"startTime":"0","endTime":"0","summary":"Summit Therapeutics公司宣布，已正式启动一项针对膀胱癌的全球性II/III期临床试验——Harmoni-Gu1研究。该试验旨在评估其候选药物Ivonescimab的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148778913","title":"异动解读 | Summit Therapeutics夜盘大跌5.54%，第二季度财报发布引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1148778913","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148778913?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:06","pubTimestamp":1784851586,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（SMMT）在今日夜盘交易时段股价大幅下挫5.54%，引发了市场的广泛关注。消息面上，公司于盘后发布了截至2026年6月30日的第二季度及上半年财务业绩与运营进展报告。尽管新闻稿未详细披露具体财务数据，但股价在报告公布后随即出现显著下跌，显示市场对其业绩表现或未来展望可能感到失望。Summit Therapeutics在报告中同步更新了其在核心管线推进及战略布局方面的阶段性进展。投资者将密切关注后续更多的财务细节及管理层解读，以评估此次股价波动的合理性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159318299","title":"Summit Therapeutics 拟通过销售代理发行及出售总价值最高达3.8亿美元的普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1159318299","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159318299?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:51","pubTimestamp":1784839908,"startTime":"0","endTime":"0","summary":"据美国证券交易委员会（SEC）文件披露，Summit Therapeutics 公司宣布了一项重大融资计划。该公司计划通过一家销售代理机构，进行普通股的发行与出售。此次拟发行的股票总价值，最高可达3.8亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156544666","title":"异动解读 | Summit Therapeutics盘后大跌6.03%，第二季度财务业绩发布引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1156544666","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156544666?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:36","pubTimestamp":1784838986,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（SMMT）今日盘后股价大幅下挫6.03%，引发市场广泛关注。消息面上，公司于盘后发布了截至2026年6月30日的第二季度及上半年财务业绩与运营进展报告。尽管新闻稿未详细披露具体财务数据，但股价在报告公布后随即出现显著下跌，显示市场对其业绩表现或未来展望可能感到失望。Summit Therapeutics在报告中同步更新了其在核心管线推进及战略布局方面的阶段性进展。投资者将密切关注后续更多的财务细节及管理层解读，以评估此次股价波动的合理性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116827920","title":"Summit Therapeutics公布2026年第二季度及上半年财务业绩与运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1116827920","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116827920?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:09","pubTimestamp":1784837376,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC（以下简称“Summit”）正式披露了截至2026年6月30日的第二季度及上半年的财务数据，并同步更新了公司在运营层面取得的阶段性进展。本次报告不仅呈现了公司在过去几个月的财务健康状况，还勾勒出其在推进核心管线及战略布局方面的关键动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653071107","title":"欧洲车市强势反弹！6月销量创近三年最大涨幅 电动车成“救命稻草”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653071107","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653071107?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:42","pubTimestamp":1784788955,"startTime":"0","endTime":"0","summary":"欧洲6月新车销量增长13%法国和德国是欧洲最大的电动车市场。除波兰外，欧洲其他所有国家的电动车销量均实现增长。今年3月，奇瑞汽车旗下捷途7车型成为英国销量最高的汽车。这些企业目前正面临国内生产成本高企、以及在全球最大汽车市场中国销量低迷的双重压力。欧洲最大汽车制造商大众汽车正陷入迄今最严重的危机之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180108436","title":"Arcus Biosciences与Summit Therapeutics达成临床试验合作，评估Casdatifan联合Ivonescimab治疗肾癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1180108436","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180108436?lang=zh_cn&edition=full","pubTime":"2026-07-23 04:32","pubTimestamp":1784752323,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc. (RCUS) 与 Summit Therapeutics PLC (SMMT) 宣布达成一项临床试验合作，旨在评估Casdatifan与Ivonescimab联合疗法在肾癌治疗中的潜力。该合作将探索两种研究性药物的协同作用，为肾细胞癌患者开发新的治疗选择。双方将整合各自的研发资源与专业知识，共同推进此项临床研究，以期加速创新疗法的开发进程。这项合作标志着两家公司在肿瘤免疫治疗领域深化探索，致力于应对未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165080744","title":"Ivonescimab联合化疗在HARMONi全球III期研究最新分析中，于西方与亚洲患者中展现一致且良好的总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165080744","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165080744?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:32","pubTimestamp":1784716350,"startTime":"0","endTime":"0","summary":"在HARMONi全球III期研究的最新分析中，Ivonescimab联合化疗方案在西方患者群体与亚洲患者群体中，均展示出具有一致性且令人鼓舞的总生存期获益。该结果进一步支持了该联合疗法在不同人群中的广泛适用性与积极疗效前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154355492","title":"Summit Therapeutics 联合疗法在亚裔及西方患者中展现积极总生存期趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1154355492","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154355492?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:31","pubTimestamp":1784716281,"startTime":"0","endTime":"0","summary":"Summit Therapeutics 公司宣布，其核心候选药物 Ivonescimab 联合化疗方案，在针对亚洲与西方患者群体的临床研究中，呈现出积极的总生存期趋势。这一进展进一步验证了该联合疗法的潜在疗效，有望为相关患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":-0.1255},{"period":"1month","weight":0.097},{"period":"3month","weight":0.1142},{"period":"6month","weight":-0.0585},{"period":"1year","weight":-0.2295},{"period":"ytd","weight":-0.1075}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2013年11月22日在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.042597},{"month":5,"riseRate":0.5,"avgChangeRate":0.075963},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.093606},{"month":7,"riseRate":0.583333,"avgChangeRate":0.072153},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002579},{"month":9,"riseRate":0.416667,"avgChangeRate":0.081296},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}